Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
IPO Year: 2000
Exchange: NASDAQ
Website: sangamo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $7.00 | Hold → Buy | Truist |
| 12/10/2024 | $10.00 | Buy | H.C. Wainwright |
| 11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
| 2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
| 1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
| 6/13/2022 | $5.00 | Neutral | Wedbush |
SCHEDULE 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
EFFECT - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
S-8 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
S-3 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A that it has co-developed with, and licensed to Pfizer Inc., following a decision by Pfizer to terminate the global collaboration and license agreement between the parties. Sangamo
- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales - TOKYO and RICHMOND, Calif., Dec. 19, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage
- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated v
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Neuropathic pain can be caused by a broad array of pathologies impacting the central or peripheral nervous systems, such as surgical trauma, spinal cord injury, nerve compression, neurological and infectious diseases, o
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo has co-developed with and licensed to Pfizer, via a platform presentation at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition. Received $50 million in upfront licens
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, November 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call wit
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. - FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway. - Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025. Sa
Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo is co-developing with and licensing to Pfizer. Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for F
Agreement leverages Sangamo's proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases Sangamo expected to receive $50 million in near-term upfront license fees and milestone payments and is eligible to earn up to $1.9 billion in development and commercial milestone payments across multiple medicines, as well as tiered royalties on net sales Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, August 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with t
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo has co-developed with and licensed to Pfizer, via a platform presentation at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition. Received $50 million in upfront licens
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, November 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call wit
Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo is co-developing with and licensing to Pfizer. Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for F
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, August 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with t
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 9, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe
Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting prion disease and tauopathies resulting in potent and widespread repression of target genes. Chronic neuropathic pain and prion disease preclinical programs advance, with investigational new drug (IND) and clinical trial authorization (CTA) submissions expected in the fourth quarters of 2024 and 2025, respectively. Announced U.S. Food and Drug Administration (FDA) alignment on an abbreviated pat
Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous administration. Demonstrated industry-leading brain tropism and enrichment in NHPs, resulting in 700-fold higher transgene expression than benchmark capsid AAV9. Capsid-enabled delivery of zinc finger payloads targeting prion disease and tauopathies resulted in robust and widespread repression of target genes. STAC-BBB capsid could potentially unlock multiple neurology epigenetic regulation programs paused by Sangamo pending identification of suitable capsid and could be advanced either
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024. The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into
Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. Dosed a total of 25 patients in Phase 1/2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional investments in Phase 3 planning until collaboration partner or Phase 3 trial funding secured. Actively seeking collaboration partners or direct investors in CAR-Treg cell therapy programs. Deferring new investments until collaboration partner or external investment is secured. Announced p
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023. The Company will hold a conference call at 8:30 a.m. ET on Thursday, November 2, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
3 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo’s Chief Executive Officer. Sangamo also announced today that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scientific Officer. Dr. Fontenot has served as Sangamo’s Head of Cell Therapy since March 2019 and as the acting Interim Head of Research since June 2020. “I am delighted to welcome Rob to Sangamo
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021. “Sung has contributed significantly to Sangamo’s evolution, helping us build a strong cash position to advance proprietary medicines for patients in need as we begin a year with several potential catalysts,” said Sandy Macrae, Chief Executive Officer of Sangamo. “I have deep appreciation for the integrity and leadership Sung brought to Sangamo. The management team and board of directors at Sangamo join me
Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00
H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00
RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously
BofA Securities downgraded Sangamo Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $5.00 previously
Wedbush upgraded Sangamo Therapeutics from Neutral to Outperform and set a new price target of $16.00
BofA Securities downgraded Sangamo Therapeutics from Buy to Neutral and set a new price target of $5.00 from $8.00 previously
Wedbush resumed coverage of Sangamo Therapeutics with a rating of Neutral and set a new price target of $5.00
RBC Capital initiated coverage of Sangamo Therapeutics with a rating of Outperform and set a new price target of $22.00
RBC Capital initiated coverage of Sangamo Therapeutics with a rating of Sector Perform and set a new price target of $22.00
Wells Fargo & Company reiterated coverage of Sangamo Therapeutics with a rating of Overweight and set a new price target of $29.00 from $36.00 previously
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)